NCT00333112

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESIcare® In Combination With Tamsulosin in OAB Residual Symptoms

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 398 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: Male
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.

Detailed description

A 2 arm study ( 1 Active, 1 Placebo) to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men

Conditions

• Urinary Incontinence

Interventions

Type	Name	Description
DRUG	solifenacin succinate	Oral
DRUG	tamsulosin	oral
DRUG	placebo	oral

Timeline

• Start date: 2006-05-01
• Primary completion: 2007-01-01
• Completion: 2007-01-01
• First posted: 2006-06-02
• Last updated: 2014-09-18

Locations

74 sites across 1 country: United States